Home page > OLD Wealth and Equity | Pharmaceuticals and Medical Devices | WTO Cancun Ministerial, September 2003 | Quality health systems and services | Medicines, health technology and health information | Irish Presidency priorities

Pharmaceuticals and Medicines

Please find all related articles below.

[Event announcement] Pharma Pollution: An Ignored Cause of Antimicrobial Resistance

REGISTER NOW Join EPHA, Health Care Without Harm, and MEP hosts Martin Hausling (Greens/EFA) and Jasenko Selimovic (ALDE) to discuss a long-neglected cause of antimicrobial resistance (AMR) - pollution of the natural environment arising from irresponsible antibiotic manufacturing and untransparent global supply chains, as well as from the overuse of antibiotics in veterinary medicine. Speakers will include representatives from civil society, the pharmaceutical industry, as well as EU and (...)

Pharmaceutical supply chains: what action is being taken?

EPHA, together with US consumer organisation SumOfUs and UK-based Ethical Consumer, has co-signed letters to some of the world’s leading pharmaceutical companies, asking for information on their sources of active pharmaceutical ingredients (APIs) and their production practices. The recent report, ’Bad Medicine’ published by SumOfUs, provides the context for the letters. It exposes the fact that a number of large pharmaceutical companies are sourcing antibiotic ingredients (...)

Added therapeutic value of medicines: EPHA/Wemos event in the European Parliament

On 15 July 2015 EPHA and Wemos hosted an event in the Members’ Salon at the European Parliament to highlight the issue of added therapeutic value (ATV) in medicines. Several studies carried out at EU member state level indicate that the majority of medicines authorised for use have little-to-no ATV in comparison with existing treatments. This means that public money is being spent on new, costly medicines which have limited ATV, whilst also using up resources which might otherwise be (...)

Evaluation of the Regulation on Tiered Pricing of Medicines

Supplying poor and developing countries with medicines at sustainable, reduced prices is one of the most important tools in the fight against major diseases, especially the “Big Three”, namely HIV, TB and malaria. After more than a decade since the Council Regulation (EC) 953/2003 came into force, to avoid trade diversion into the European Union of certain key medicines, stakeholders came together to discuss the overall impact of the Regulation at a workshop on 15 July 2015, (...)

AMR’s multiple dimensions call for action on all fronts

The June Uppsala Health Summit (UHS), ‘A World Without Antibiotics’ expanded the discussion about antimicrobial resistance (AMR) at European and national level by examining this critical health threat from different angles. Among the key themes discussed were access to antibiotics and to improved diagnostics, the environmental dimension of AMR, collaborative research & innovation, and economic models allowing pharma companies to balance profits and investments for the public (...)

New report exposes link between global pharmaceutical production and anti-microbial resistance

A new report released on 11 June 2015 by global consumer watchdog SumOfUs.org provides a new angle to the debate about the major health threat of antimicrobial resistance (AMR): the improper disposal of pharmaceutical waste by polluting factories in China, and their links with some of the world’s biggest pharmaceutical companies. The report raises the urgent need for antibiotic stewardship to avoid a looming public health disaster. According to the report, polluting factories in (...)

20th EAHP congress focuses on patient safety & changing roles of hospital pharmacists

The 20th congress of EPHA member the European Association of Hospital Pharmacists (EAHP) took place in Hamburg on 25-27 March 2015. This year’s focus was ’patient safety first’, and various sessions explored how hospital pharmacists can contribute to the patient journey, for example by ensuring medication reconciliation and safety and by providing expert advice on treatments and medicines. EPHA President Peggy Maguire - also Director General of the European Institute of (...)

European Medicines Agency - Draft Proposal on Transparency Addendum

In a recent public consultation, the European Medicines Agency (EMA) solicited stakeholders’ views about its draft proposal for a transparency addendum pertaining to the content of the EU portal and database that will be set up for the implementation of the Clinical Trial Regulation No 536/2014. The express aim of the latter is to provide more information on clinical trials and their result in Europe. The consultation on the ’Draft proposal for an addendum, on transparency, to (...)

[Press release] European Antibiotic Awareness Day: Fighting ‘superbugs’ to save lives

Brussels, 18 November – Today marks the 7th European Antibiotic Awareness Day (EAAD) (1) which promotes a more prudent use of antibiotics to tackle the growing challenge of multi-drug resistant ‘superbugs’ (2). Around 25,000 patients die every year in the European Union (EU) as a result of infections caused by antibiotic-resistant bacteria. Preventing the spread of antibiotic resistance will lead to significant health service savings since related costs amount to (...)

[Report] Patients suffering from medicines shortages in all European countries

A new report on medicines shortages experienced in European healthcare systems reveals that over 86% of hospital pharmacists are experiencing difficulties in sourcing medicines with 66% reporting this as a daily or weekly problem. The top affected areas are medicines to fight infection, cancer drugs and anesthetics. Brussels, 17 November 2014 - The report by the European Association of Hospital Pharmacists (EAHP), surveyed the experiences of over 600 hospital pharmacists in 36 European (...)